When is GYRE's latest earnings report released?
The most recent financial report for Gyre therapeutics, inc. (GYRE) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GYRE's short-term business performance and financial health. For the latest updates on GYRE's earnings releases, visit this page regularly.
Where does GYRE fall in the P/E River chart?
According to historical valuation range analysis, Gyre therapeutics, inc. (GYRE)'s current price-to-earnings (P/E) ratio is 104.43, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of GYRE?
According to the latest financial report, Gyre therapeutics, inc. (GYRE) reported an Operating Profit of 6.93M with an Operating Margin of 22.66% this period, representing a growth of 63.6% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is GYRE's revenue growth?
In the latest financial report, Gyre therapeutics, inc. (GYRE) announced revenue of 30.56M, with a Year-Over-Year growth rate of 19.92%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does GYRE have?
As of the end of the reporting period, Gyre therapeutics, inc. (GYRE) had total debt of 1.17M, with a debt ratio of 0.01. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does GYRE have?
At the end of the period, Gyre therapeutics, inc. (GYRE) held Total Cash and Cash Equivalents of 40.4M, accounting for 0.25 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does GYRE go with three margins increasing?
In the latest report, Gyre therapeutics, inc. (GYRE) achieved the “three margins increasing” benchmark, with a gross margin of 94.7%%, operating margin of 22.66%%, and net margin of 11.8%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess GYRE's profit trajectory and future growth potential.
Is GYRE's EPS continuing to grow?
According to the past four quarterly reports, Gyre therapeutics, inc. (GYRE)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.04. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of GYRE?
Gyre therapeutics, inc. (GYRE)'s Free Cash Flow (FCF) for the period is 4.01M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 289.88% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of GYRE?
The latest valuation data shows Gyre therapeutics, inc. (GYRE) has a Price-To-Earnings (PE) ratio of 104.43 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
